Safety and Efficacy of Insulin Detemir in Combination With OADs in Type 2 Diabetes

Evaluation of Insulin Detemir in Combination With OADs in Type 2 Diabetes Mellitus

This trial is conducted in Asia.

The aim of this trial is to evaluate the blood glucose achieved with insulin detemir as add-on to current oral antidiabetic drug (OAD) treatment in subjects with type 2 diabetes.

Inclusion Criteria:

• Type 2 diabetes for at least 12 months since diagnosis
• Insulin naive subjects
• OAD treatment for at least 4 months with max. two OAD treatments
• Body mass index below 30.0 kg/m2
• HbA1c between 7.0-11.0%

Exclusion Criteria:

• OAD treatment with three or more OADs
• Secondary diabetes
• Known hypoglycaemia unawareness or recurrent major hypoglycaemia as judged by the Investigator
• Uncontrolled hypertension
• Known or suspected allergy to trial product or related products